增持后，JPMorgan Chase & Co.最新持好仓数目为8684.107万股，持好仓比例由4.98%上升至5.06%。 | 股份代號: | 01801 | | --- | --- | | 上市法國名稱: | 信建生物製藥 | | 日期(日 / 月 / 年): | 18/10/2025 - 18/11/2025 | 格隆汇11月18日丨根据联交所最新权益披露资料显示，2025年11月11日，信达生物(01801.HK)获JPMorgan Chase & Co.以每股均价84.7327港元增持好仓 143.88万股，涉资约1.22亿港元。 | Frida Barra | 大 股東/董事/最高行政人員名 作出披露的 買 入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法國 | | --- | --- | --- | --- | --- | --- | | | 版 分享 三 | | | 和人员上面落語 | 有投票樓股期(日/月/ 份權益 | | | | | | | 份自分比 年) | | CS20251114E00461 | JPMorgan Chase & ...

智通财经APP获悉，香港联交所最新资料显示，11月11日，小摩增持信达生物(01801)143.8757万股，每 股作价84.7327港元，总金额约为1.22亿港元。增持后最新持股数目约为8684.11万股，最新持股比例为 5.06%。 ...

Group 1 - JPMorgan increased its stake in Innovent Biologics (01801) by acquiring 1,438,757 shares at a price of HKD 84.7327 per share, totaling approximately HKD 122 million [1] - Following the acquisition, JPMorgan's total shareholding in Innovent Biologics is approximately 86,841,100 shares, representing a stake of 5.06% [1]

Core Viewpoint - Cinda Biologics reported a year-on-year revenue growth of over 40% in Q3, exceeding expectations and indicating strong performance in the biopharmaceutical sector [1] Group 1: Financial Performance - Total product revenue for Cinda Biologics in Q3 surpassed 3.3 billion, with a quarterly growth of 22%, outpacing last year's 15% growth [1] - The company is expected to achieve an annual revenue of approximately 11.5 billion, primarily driven by the sales of Masituzumab and three recently licensed candidate drugs to Takeda [1] Group 2: Future Projections - The firm has raised its total product revenue forecasts for 2025 to 2027 by 1%, 2%, and 1% respectively, projecting revenues of 11.5 billion, 18.3 billion, and 23.3 billion [1] - Adjusted profit forecasts have also been increased to 1.7 billion, 10.3 billion, and 5.6 billion for the same period [1] Group 3: Market Position and Rating - Cinda Biologics is viewed as a leader in biopharmaceuticals for treating challenging chronic and fatal diseases in China [1] - The target price has been raised from 125 HKD to 128 HKD, corresponding to a projected price-to-sales ratio of 10.6 times for 2026, maintaining an "outperform" rating and listing it as a preferred stock in the industry [1]

Core Viewpoint - Jianyin International has raised the target price for Innovent Biologics (01801) by 2.4% from HKD 125 to HKD 128, maintaining a "Outperform" rating, citing the company's robust fundamentals as a preferred stock choice [1] Financial Performance - Innovent Biologics reported total product revenue exceeding RMB 3.3 billion in Q3, representing an annual increase of over 40%, surpassing the previous forecast of a 37% annual growth for total product revenue in 2025 [1] - The revenue forecasts for 2025, 2026, and 2027 have been adjusted upwards by 1%, 2%, and 1% respectively, reaching RMB 11.5 billion, RMB 18.3 billion, and RMB 23.3 billion [1] Strategic Developments - The company has reached an agreement with Takeda Pharmaceutical regarding an authorization deal, expecting to receive a prepayment of USD 1.1 billion by the end of 2026 [1] - As a result of this agreement, the adjusted profit forecasts for 2025, 2026, and 2027 have been increased to RMB 5.6 billion [1]

Core Viewpoint - Jianyin International has raised the target price for Innovent Biologics (01801) by 2.4% from HKD 125 to HKD 128, maintaining a "Outperform" rating, citing the company's robust fundamentals as a preferred stock choice [1] Financial Performance - Innovent Biologics reported total product revenue exceeding RMB 3.3 billion in Q3, representing an annual increase of over 40%, surpassing the previous forecast of a 37% annual growth for total product revenue in 2025 [1] - The revenue forecasts for 2025, 2026, and 2027 have been adjusted upwards by 1%, 2%, and 1% respectively, reaching RMB 11.5 billion, RMB 18.3 billion, and RMB 23.3 billion [1] Strategic Developments - The company has reached an agreement with Takeda Pharmaceutical regarding an authorization deal, expecting to receive an upfront cash reward of USD 1.1 billion by the end of 2026 [1] - As a result of this agreement, the adjusted profit forecasts for 2025, 2026, and 2027 have been increased to RMB 5.6 billion [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 信達生物製藥 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01801 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 F ...

Group 1 - The core viewpoint of the report indicates that Hansoh Pharmaceutical (03692) is expected to have smooth sales of existing products in the second half of the year, with an $80 million upfront payment from Roche expected to be recognized by the end of 2025, which will facilitate the development of HS-20110 [1] - Innovating drugs are making significant progress in international markets, with Hansoh Pharmaceutical granting Roche exclusive global rights for the antibody-drug conjugate HS20110 outside Greater China, and Innovent Biologics (01801) collaborating with Takeda to advance new generation tumor immunotherapy (IO) and antibody-drug conjugates (ADC) [3] - The eleventh batch of centralized procurement in mainland China has included 55 types of drugs, but the impact on major Hong Kong pharmaceutical companies like Hansoh Pharmaceutical, CSPC Pharmaceutical Group (01093), and China National Pharmaceutical Group (01177) is expected to be limited as none of their core products are involved [4] Group 2 - The Hang Seng Healthcare Index underperformed the Hang Seng Index in October, declining by 11.1%, primarily due to concerns over potential impacts from increased drug tariffs in the U.S. and the upcoming expiration of the patent for the weight-loss drug semaglutide in China in 2026 [2] - The collaboration between Innovent Biologics and Takeda is expected to accelerate the development of tumor immunotherapy and ADCs, benefiting both product development and sales [3] - The report highlights that Roche's extensive experience in ADC development is likely to ensure the smooth progress of HS20110's development [3]

Group 1 - The core viewpoint of the report indicates that Hansoh Pharmaceutical (03692) is expected to have smooth sales in the second half of the year, with an $80 million upfront payment from Roche expected to be recognized by the end of 2025, which will facilitate the development of HS-20110 [1] - Innovating drugs are making significant progress in international markets, with Hansoh Pharmaceutical granting Roche exclusive global rights for HS-20110 outside Greater China, and Innovent Biologics (01801) collaborating with Takeda to advance new generation tumor immunotherapy (IO) and antibody-drug conjugates (ADC) [2] - The Hang Seng Healthcare Index underperformed the Hang Seng Index in October, declining by 11.1%, attributed to concerns over potential impacts of increased drug tariffs in the U.S. and the upcoming expiration of the patent for the weight-loss drug semaglutide in China in 2026 [1][2] Group 2 - The eleventh batch of national volume-based procurement in mainland China included 55 types of drugs, with major Hong Kong pharmaceutical companies like Hansoh Pharmaceutical, CSPC Pharmaceutical Group (01093), and China Biologic Products (01177) having products selected, but none of their core products were affected [3] - The collaboration with Roche is expected to enhance the development of HS-20110 due to Roche's extensive experience in ADC development, while the partnership with Takeda is anticipated to benefit both product development and sales due to Takeda's strong sales network in Japan and the U.S. [2]

Group 1 - JPMorgan Chase & Co. increased its stake in Innovent Biologics (01801.HK) by acquiring 2.5505 million shares at an average price of HKD 80.6819 per share, totaling approximately HKD 206 million [1] - Following this acquisition, JPMorgan's total holdings in Innovent Biologics rose to 87,023,236 shares, increasing its ownership percentage from 4.92% to 5.07% [1]